What is HC Wainwright’s Estimate for SGMO FY2026 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a note issued to investors on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of ($0.20) per share for the year, down from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2026 earnings at ($0.05) EPS, FY2027 earnings at ($0.05) EPS, FY2028 earnings at $0.14 EPS, FY2029 earnings at $0.25 EPS and FY2030 earnings at $0.35 EPS.

Other research analysts have also recently issued reports about the company. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Zacks Research cut Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Reduce” and a consensus target price of $5.50.

Sangamo Therapeutics Stock Up 8.0%

SGMO stock opened at $0.20 on Thursday. Sangamo Therapeutics has a twelve month low of $0.10 and a twelve month high of $0.77. The stock has a market cap of $82.86 million, a P/E ratio of -0.45 and a beta of 1.04. The business’s 50-day moving average price is $0.23 and its 200-day moving average price is $0.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Sangamo Therapeutics by 23.9% during the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock valued at $7,817,000 after acquiring an additional 2,240,422 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Sangamo Therapeutics by 1,856.1% during the 1st quarter. Bank of America Corp DE now owns 1,838,390 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 1,744,406 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Sangamo Therapeutics by 182.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock valued at $1,669,000 after acquiring an additional 1,602,107 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Sangamo Therapeutics by 63.1% during the 3rd quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after acquiring an additional 1,417,029 shares during the last quarter. Finally, Wasatch Advisors LP boosted its position in shares of Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after acquiring an additional 1,215,653 shares during the last quarter. 56.92% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $0.26, for a total value of $89,944.92. Following the transaction, the senior vice president directly owned 332,769 shares of the company’s stock, valued at approximately $86,519.94. The trade was a 50.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.10% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.